Utilization and Outcomes of Children Treated with Direct Thrombin Inhibitors on Paracorporeal Ventricular Assist Device Support
- 20 November 2019
- journal article
- research article
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 66 (8) , 939-945
Abstract
Thrombotic and bleeding complications have historically been major causes of morbidity and mortality in pediatric ventricular assist device (VAD) support. Standard anticoagulation with unfractionated heparin is fraught with problems related to its heterogeneous biochemical composition and unpredictable pharmacokinetics. We sought to describe the utilization and outcomes in children with paracorporeal VAD support who are treated with direct thrombin inhibitors (DTIs) antithrombosis therapy. Retrospective multicenter review of all pediatric patients (aged <19 years) treated with a DTI (bivalirudin or argatroban) on paracorporeal VAD support, examining bleeding and thrombotic adverse events. From May 2012 to 2018, 43 children (21 females) at 10 centers in North America, median age 9.5 months (0.1–215 months) weighing 8.6 kg (2.8–150 kg), were implanted with paracorporeal VADs and treated with a DTI. Diagnoses included cardiomyopathy 40% (n = 17), congenital heart disease 37% (n = 16; single ventricle n = 5), graft vasculopathy 9% (n = 4), and other 14% (n = 6). First device implanted included Berlin Heart EXCOR 49% (n = 21), paracorporeal continuous flow device 44% (n = 19), and combination of devices in 7% (n = 3). Adverse events on DTI therapy included; major bleeding in 16% (n = 7) (2.6 events per 1,000 patient days of support on DTI), and stroke 12% (n = 5) (1.7 events per 1,000 patient days of support on DTI). Overall survival to transplantation (n = 30) or explantation (n = 8) was 88%. This is the largest multicenter experience of DTI use for anticoagulation therapy in pediatric VAD support. Outcomes are encouraging with lower major bleeding and stroke event rate than that reported in literature using other anticoagulation agents in pediatric VAD support.Keywords
This publication has 29 references indexed in Scilit:
- Incremental Reduction in the Incidence of Stroke in Children Supported With the Berlin EXCOR Ventricular Assist DeviceThe Annals of Thoracic Surgery, 2013
- Antithrombotic strategies in children receiving long-term Berlin Heart EXCOR ventricular assist device therapyThe Journal of Heart and Lung Transplantation, 2013
- Bivalirudin Versus Heparin as an Anticoagulant During Extracorporeal Membrane Oxygenation: A Case-Control StudyJournal of Cardiothoracic and Vascular Anesthesia, 2013
- Prospective Trial of a Pediatric Ventricular Assist DeviceNew England Journal of Medicine, 2012
- Developmental haemostasis: Secondary haemostasisSeminars in Fetal and Neonatal Medicine, 2011
- Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenationCritical Care, 2011
- Update on heparin: what do we need to know?Journal of Thrombosis and Thrombolysis, 2009
- Monitoring direct thrombin inhibitors with a plasma diluted thrombin timeThrombosis and Haemostasis, 2007
- Therapeutic range for unfractionated heparin therapy: age‐related differences in response in childrenJournal of Thrombosis and Haemostasis, 2006
- Anticoagulant Action of HeparinNature, 1973